Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Transarterial VSV oncolytic therapy for hepatocellular carcinoma

17.11.2011
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, with the majority of clinical cases arising as a result of the wound-healing response to chronic liver injury known as hepatic fibrosis. If left untreated, the condition progresses to the state of cirrhosis with severe complications of end-stage liver disease including HCC. When HCC arises under these conditions, it presents a major clinical challenge for treatment of the cancer as well as the underlying liver disease.

<br> Based on the results of early clinical trials, oncolytic virotherapy holds promise as a safe and effective treatment strategy for advanced HCC. It has been demonstrated that recombinant vesicular stomatitis virus (VSV) vectors are particularly attractive oncolytic agents for the treatment of HCC, resulting in significant tumor responses and subsequent prolongation of survival. <br> Over the last 25 years, much progress has been made in understanding the mechanism of liver fibrogenesis, and as a result, it is now believed that fibrosis and cirrhosis are reversible processes. Despite this growing body of evidence, the clinical management of cirrhosis has fallen behind, and the success of available therapies has yet to be demonstrated. The challenge for a successful and safe antifibrotic therapy is specific targeting of the responsible cell types involved in fibrotic progression, without the introduction of collateral toxicities. In a preclinical rodent model of HCC with underlying fibrosis it could be shown that VSV administered by hepatic arterial infusion does not only maintain its ability to efficiently and selectively kill tumor cells, but it also possesses antifibrotic properties which provides the unique benefit in concomitant reversal of fibrotic progression with a single agent. Therefore, this innovation represents a significant therapeutic advantage over the current state of the art.



Further Information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

info@technologieallianz.de | TechnologieAllianz e.V.
Further information:
http://www.technologieallianz.de/angebote.php?sort=sag&id=2211&lang=en
http://www.technologieallianz.de

More articles from Technology Offerings:

nachricht New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.

nachricht Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.

All articles from Technology Offerings >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Staying in Shape

16.08.2018 | Life Sciences

Diving robots find Antarctic seas exhale surprising amounts of carbon dioxide in winter

16.08.2018 | Earth Sciences

Protein droplets keep neurons at the ready and immune system in balance

16.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>